WAM
SABSW icon

Wolverine Asset Management’s SAB Biotherapeutics Warrant SABSW Stock Holding History

Wolverine Asset Management’s Portfolio SABSW Stock Details SABSW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$47 Hold
1,811
– – ﹤0.01% 1662
2025
Q4 		$57 Hold
1,811
– – ﹤0.01% 1632
2025
Q3 		$42 Sell
1,811
-2,809
-61% -$94 ﹤0.01% 1576
2025
Q2 		$153 Hold
4,620
– – ﹤0.01% 1564
2025
Q1 		$161 Sell
4,620
-4,035
-47% -$226 ﹤0.01% 1529
2024
Q4 		$651 Sell
8,655
-6,864
-44% -$414 ﹤0.01% 1534
2024
Q3 		$558 Buy
15,519
+200
+1% +$7 ﹤0.01% 1559
2024
Q2 		$726 Sell
15,319
-7,464
-33% -$276 ﹤0.01% 1560
2024
Q1 		$888 Sell
22,783
-27
-0.1% -$1 ﹤0.01% 1525
2023
Q4 		$688 Buy
22,810
+10,045
+79% +$605 ﹤0.01% 1638
2023
Q3 		$893 Buy
12,765
+3,400
+36% +$313 ﹤0.01% 1707
2023
Q2 		$977 Sell
9,365
-3,425
-27% -$358 ﹤0.01% 1643
2023
Q1 		$460 Hold
12,790
– – ﹤0.01% 1761
2022
Q4 		$601 Buy
12,790
+11,169
+689% +$681 ﹤0.01% 1982
2022
Q3 		$0 Buy
+1,621
New +$193 ﹤0.01% 2494
2021
Q3 		– Sell
-11,855
Closed -$10K – 2299
2021
Q2 		$10K Sell
11,855
-35,209
-75% -$25.6K ﹤0.01% 1994
2021
Q1 		$28K Buy
+47,064
New +$48.9K ﹤0.01% 1727

Other funds holding SABSW

LP
LMR Partners London, United Kingdom $45.4B AUM 60.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wolverine Asset Management's SABSW Position: Q1 2026 in Review

Wolverine Asset Management held its SAB Biotherapeutics Warrant (SABSW) position steady in Q1 2026 at 1,811 shares worth $47. The position accounts for ﹤0.01% of the portfolio, ranked #1662.

Wolverine Asset Management first reported a position in SABSW in Q1 2021 and has held it in 17 quarters since. The position peaked at $28K in Q1 2021. 6 funds tracked by Wall St. Rank hold SABSW as of Q1 2026.

  • Wolverine Asset Management held 1,811 shares of SAB Biotherapeutics Warrant worth $47 as of Q1 2026.
  • Wolverine Asset Management left its SAB Biotherapeutics Warrant share count unchanged in Q1 2026.
  • SAB Biotherapeutics Warrant made up ﹤0.01% of Wolverine Asset Management's portfolio in Q1 2026, its #1662 holding.
  • Wolverine Asset Management first reported a position in SAB Biotherapeutics Warrant in Q1 2021 and has held it in 17 quarters since.
  • Wolverine Asset Management's SAB Biotherapeutics Warrant position peaked at $28K in Q1 2021.
  • 6 funds tracked by Wall St. Rank held SAB Biotherapeutics Warrant as of Q1 2026.

Based on Wolverine Asset Management's 13F filing for Q1 2026, filed 4 May 2026.